▶ 調査レポート

巣状分節性糸球体硬化症(FSGS)の世界市場分析・規模・シェア・成長・動向・予測:疾病種類別、疾病管理法別

• 英文タイトル:Focal Segmental Glomerulosclerosis (FSGS) Market (Disease Type - Primary Focal Segmental Glomerulosclerosis and Secondary Focal Segmental Glomerulosclerosis; Disease Management - Diagnosis (Kidney Biopsy and Creatine Test) and Treatment (Drug Therapy, Dialysis, and Kidney Transplant) Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025

Transparency Market Researchが調査・発行した産業分析レポートです。巣状分節性糸球体硬化症(FSGS)の世界市場分析・規模・シェア・成長・動向・予測:疾病種類別、疾病管理法別 / Focal Segmental Glomerulosclerosis (FSGS) Market (Disease Type - Primary Focal Segmental Glomerulosclerosis and Secondary Focal Segmental Glomerulosclerosis; Disease Management - Diagnosis (Kidney Biopsy and Creatine Test) and Treatment (Drug Therapy, Dialysis, and Kidney Transplant) Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025 / TPM-B04464資料のイメージです。• レポートコード:TPM-B04464
• 出版社/出版日:Transparency Market Research / 2018年1月
• レポート形態:英文、PDF、163ページ
• 納品方法:Eメール
• 産業分類:製薬・医療
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Multi User¥1,301,660 (USD8,795)▷ お問い合わせ
  Global Site License¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、巣状分節性糸球体硬化症(FSGS)の世界市場について調べ、巣状分節性糸球体硬化症(FSGS)の世界規模、市場動向、市場環境、疾病種類別分析、疾病管理法別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・巣状分節性糸球体硬化症(FSGS)の世界市場動向
・巣状分節性糸球体硬化症(FSGS)の世界市場環境
・巣状分節性糸球体硬化症(FSGS)の世界市場規模
・巣状分節性糸球体硬化症(FSGS)の世界市場規模:疾病種類別
・巣状分節性糸球体硬化症(FSGS)の世界市場規模:疾病管理法別
・巣状分節性糸球体硬化症(FSGS)の世界市場:地域別市場規模・分析
・巣状分節性糸球体硬化症(FSGS)の北米市場規模・予測
・巣状分節性糸球体硬化症(FSGS)のアメリカ市場規模・予測
・巣状分節性糸球体硬化症(FSGS)の中南米市場規模・予測
・巣状分節性糸球体硬化症(FSGS)のヨーロッパ市場規模・予測
・巣状分節性糸球体硬化症(FSGS)のアジア市場規模・予測
・巣状分節性糸球体硬化症(FSGS)の日本市場規模・予測
・巣状分節性糸球体硬化症(FSGS)の中国市場規模・予測
・巣状分節性糸球体硬化症(FSGS)のインド市場規模・予測
・巣状分節性糸球体硬化症(FSGS)の中東市場規模・予測
・巣状分節性糸球体硬化症(FSGS)のアフリカ市場規模・予測
・競争状況・関連企業情報

Global Focal Segmental Glomerulosclerosis (FSGS) Market: Overview

This report on focal segmental glomerulosclerosis (FSGS) market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacturing and commercialization of diagnostic and therapeutic products for focal segmental glomerulosclerosis (FSGS) as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the overall information and data analysis of the global focal segmental glomerulosclerosis (FSGS) market with respect to the leading market segments based on disease type, disease management and geographies.

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the focal segmental glomerulosclerosis (FSGS) market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global focal segmental glomerulosclerosis (FSGS) market.

Global Focal Segmental Glomerulosclerosis (FSGS) Market: Segmentation

Based on disease type, the focal segmental glomerulosclerosis (FSGS) market has been majorly segmented into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis. In terms of disease management, the focal segmental glomerulosclerosis (FSGS) market has been broadly classified into diagnosis and treatment. Diagnosis includes segments such as kidney biopsy, creatine test, and others. Treatment includes segments such as drug therapy, dialysis, and kidney transplant.

Each of the market segments have been extensively analyzed based on the market related factors such as incidence and prevalence of focal segmental glomerulosclerosis (FSGS), available treatments, and pipeline products. Moreover, historical year-on-year growth have been taken into consideration while estimating the market size. The market size and forecast in terms of US$ million for each segment has been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

Geographically, focal segmental glomerulosclerosis (FSGS) market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides market size and forecast for major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, porter’s five forces analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global focal segmental glomerulosclerosis (FSGS) market.

Global Focal Segmental Glomerulosclerosis (FSGS) Market: Competitive Dynamics

The key players operating in the focal segmental glomerulosclerosis (FSGS) market are Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., Novartis AG, Pfizer, Inc., AstraZeneca plc., Sanofi S.A, GlaxoSmithKline plc. and Teva Pharmaceutical Industries Ltd. The global focal segmental glomerulosclerosis (FSGS) market is expected to undergo change after the successful pipeline product launch during the forecast period.

The global focal segmental glomerulosclerosis (FSGS) market is segmented as follows:

Global Focal Segmental Glomerulosclerosis (FSGS) Market, by Disease Type

Primary Focal Segmental Glomerulosclerosis
Secondary Focal Segmental Glomerulosclerosis
Global Focal Segmental Glomerulosclerosis (FSGS) Market, by Disease Management

Diagnosis
Kidney Biopsy
Creatine Test
Others
Treatment
Drug Therapy
Dialysis
Kidney Transplant
Global Focal Segmental Glomerulosclerosis (FSGS) Market, by Geography

North America
U.S.
Canada
Europe
Germany
France
Italy
Spain
U.K.
Rest of Europe
Asia Pacific
India
Japan
China
Australia & New Zealand
Rest of Asia
Latin America (LATAM)
Brazil
Mexico
Rest of LATAM
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

レポート目次

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology

3. Executive Summary
3.1. Global Focal Segmental Glomerulosclerosis Market Snapshot

4. Market Overview
4.1. Product Overview
4.2. Key Industry Events
4.3. Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, 2015–2025
4.4. Market Opportunity Map
4.5. Global Focal Segmental Glomerulosclerosis Market Outlook
4.6. Overview of Clinical Trials
4.7. Global Focal Segmental Glomerulosclerosis Prevalence Scenario-2016, by Region

5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.2.1. Increasing burden of focal segmental glomerulosclerosis (FSGS)
5.2.2. Untapped market opportunities with a limited number of pipeline products
5.2.3. Efforts by non-government organizations to raise awareness
5.2.4. Strong focus on R&D activities for developing new therapies and drugs
5.2.5. Rise in funding for research on rare diseases
5.3. Restraints
5.3.1. High cost of kidney dialysis and kidney transplant treatments
5.3.2. Difficulty in recruitment for clinical trials
5.3.3. Non-availability of approved drugs and dearth of trained medical professionals
5.4. Opportunities
5.4.1. Promising pipeline of novel molecules and their approval
5.4.2. Unmet needs for management of focal segmental glomerulosclerosis (FSGS)

6. Global Focal Segmental Glomerulosclerosis Market Analysis, by Disease Type
6.1. Introduction
6.2. Key Findings
6.3. Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
6.4. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
6.4.1. Primary Focal Segmental Glomerulosclerosis
6.4.2. Secondary Focal Segmental Glomerulosclerosis
6.5. Global Focal Segmental Glomerulosclerosis Market Analysis, by Disease Type
6.6. Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type
6.7. Key Trends

7. Global Focal Segmental Glomerulosclerosis Market Analysis, by Disease Management
7.1. Introduction
7.2. Key Findings
7.3. Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
7.4. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
7.4.1. Diagnosis
7.4.2. Treatment
7.5. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
7.5.1. Kidney Biopsy
7.5.2. Creatine Test
7.5.3. Others
7.6. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
7.6.1. Drug Therapy
7.6.2. Dialysis
7.6.3. Kidney Transplant
7.7. Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management
7.8. Key Trends

8. Global Focal Segmental Glomerulosclerosis Market Analysis, by Region
8.1. Global Market Scenario, by Country
8.2. Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Region
8.3. Global Focal Segmental Glomerulosclerosis Market Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
8.4. Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Region
8.5. Regulatory Scenario by Region/Key Countries

9. North America Focal Segmental Glomerulosclerosis Market Analysis
9.1. Key Findings
9.2. North America Focal Segmental Glomerulosclerosis Market Overview
9.3. North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
9.4. North America Focal Segmental Glomerulosclerosis Market Forecast, by Country
9.4.1. U.S.
9.4.2. Canada
9.5. North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
9.6. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
9.7. North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
9.8. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
9.9. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
9.10. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
9.11. North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

10. Europe Focal Segmental Glomerulosclerosis Market Analysis
10.1. Key Findings
10.2. Europe Focal Segmental Glomerulosclerosis Market Overview
10.3. Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
10.4. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Country
10.4.1. Germany
10.4.2. U.K.
10.4.3. Spain
10.4.4. France
10.4.5. Russia
10.4.6. Poland
10.4.7. Rest of Europe
10.5. Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
10.6. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
10.7. Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
10.8. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
10.9. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
10.10. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
10.11. Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

11. Asia Pacific Focal Segmental Glomerulosclerosis Market Analysis
11.1. Key Findings
11.2. Asia Pacific Focal Segmental Glomerulosclerosis Market Overview
11.3. Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
11.4. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Country
11.4.1. India
11.4.2. Japan
11.4.3. China
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
11.6. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
11.7. Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
11.8. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
11.9. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
11.10. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
11.11. Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

12. Latin America Focal Segmental Glomerulosclerosis Market Analysis
12.1. Key Findings
12.2. Latin America Focal Segmental Glomerulosclerosis Market Overview
12.3. Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
12.4. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Country
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
12.6. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
12.7. Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
12.8. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
12.9. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
12.10. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
12.11. Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

13. Middle East & Africa Focal Segmental Glomerulosclerosis Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Focal Segmental Glomerulosclerosis Market Overview
13.3. Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
13.4. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Country
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
13.6. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
13.7. Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
13.8. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
13.9. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
13.10. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
13.11. Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

14. Competition Landscape
14.1. Competition Matrix
14.2. Company Profiles
14.2.1. Variant Pharmaceuticals, Inc.
14.2.1.1. Company Details
14.2.1.2. Business Overview
14.2.1.3. Strategic Overview
14.2.1.4. SWOT Analysis
14.2.2. ChemoCentryx, Inc.
14.2.2.1. Company Details
14.2.2.2. Business Overview
14.2.2.3. Strategic Overview
14.2.2.4. SWOT Analysis
14.2.3. Retrophin, Inc.
14.2.3.1. Company Details
14.2.3.2. Business Overview
14.2.3.3. Strategic Overview
14.2.3.4. SWOT Analysis
14.2.4. AbbVie, Inc.
14.2.4.1. Company Details
14.2.4.2. Business Overview
14.2.4.3. Financial Overview
14.2.4.4. Strategic Overview
14.2.4.5. SWOT Analysis
14.2.5. Novartis AG
14.2.5.1. Company Details
14.2.5.2. Business Overview
14.2.5.3. Financial Overview
14.2.5.4. Strategic Overview
14.2.5.5. SWOT Analysis
14.2.6. Pfizer, Inc.
14.2.6.1. Company Details
14.2.6.2. Business Overview
14.2.6.3. Financial Overview
14.2.6.4. Strategic Overview
14.2.6.5. SWOT Analysis
14.2.7. AstraZeneca plc.
14.2.7.1. Company Details
14.2.7.2. Business Overview
14.2.7.3. Financial Overview
14.2.7.4. Strategic Overview
14.2.7.5. SWOT Analysis
14.2.8. Sanofi S.A.
14.2.8.1. Company Details
14.2.8.2. Business Overview
14.2.8.3. Financial Overview
14.2.8.4. Strategic Overview
14.2.8.5. SWOT Analysis
14.2.9. GlaxoSmithKline plc.
14.2.9.1. Company Details
14.2.9.2. Business Overview
14.2.9.3. Financial Overview
14.2.9.4. Strategic Overview
14.2.9.5. SWOT Analysis
14.2.10. Teva Pharmaceutical Industries Ltd.
14.2.10.1. Company Details
14.2.10.2. Business Overview
14.2.10.3. Financial Overview
14.2.10.4. Strategic Overview
14.2.10.5. SWOT Analysis

List of Tables

TABLE 1 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 2 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 3 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 4 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 5 Global Focal Segmental Glomerulosclerosis Market Revenue (US$ Mn) Forecast, by Region, 2015–2025
TABLE 6 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country, 2015–2025
TABLE 7 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 8 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 9 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease
TABLE 10 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 11 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 12 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 13 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management,
TABLE 14 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 15 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 16 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 17 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 18 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 19 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 20 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 21 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 22 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 23 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 24 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 25 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 26 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 27 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 28 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 29 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 30 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025